Solid-forming local anesthetic formulations for pain control
View Patent ↗Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.
1. A solid-forming local anesthetic formulation comprising
from 4 wt % to 10 wt % lidocaine,
from 4 wt % to 10 wt % tetracaine,
from 10 wt % to 18 wt % polyvinyl alcohol,
from 30 wt % to 50 wt % water,
from 2 wt % to 6 wt % of sorbitan monopalmitate or sorbitan monostearate,
from 18 wt % to 32.4 wt % dicalcium phosphate, and
from 2 wt % to 13 wt % petrolatum,
wherein the water to polyvinyl alcohol weight ratio (w/w) is greater than 2.4.
2. The formulation of claim 1 , wherein the lidocaine and tetracaine are each in their base form.
3. The formulation of claim 2 , wherein the lidocaine and tetracaine are in the form of a eutectic mixture.
4. The formulation of claim 1 , wherein the polyvinyl alcohol has an average mass from about 30,000 Daltons to about 80,000 Daltons.
5. A solid-forming local anesthetic formulation, comprising:
from 4 wt % to 30 wt % of an eutectic mixture of lidocaine and tetracaine,
from 10 wt % to 18 wt % polyvinyl alcohol,
from 30 wt % to 50 wt % water,
from 2 wt % to 13 wt % petrolatum,
from 18 wt % to 32.4 wt % dicalcium phosphate, and
from 2 wt % to 6 wt % sorbitan monostearate,
wherein the water to polyvinyl alcohol weight ratio (w/w) is greater than 2.4.
6. The formulation of claim 1 , wherein the dicalcium phosphate is present at from 18 wt % to 27 wt %.
7. The formulation of claim 5 , wherein the polyvinyl alcohol has an average mass from about 30,000 Daltons to about 80,000 Daltons.
8. The formulation of claim 1 , wherein the formulation comprises sorbitan monopalmitate.
9. The formulation of claim 1 , wherein the formulation comprises sorbitan monostearate.
10. The formulation of claim 1 , wherein the water to polyvinyl alcohol ratio is greater than 2.5.
11. The formulation of claim 1 , wherein the lidocaine and tetracaine is present as a eutectic mixture at a 2:1 to 1:2 weight ratio.
12. The formulation of claim 1 , wherein the lidocaine and tetracaine is present as a eutectic mixture at about 1:1 weight ratio.
13. The formulation of claim 1 , wherein the formulation comprises 7% lidocaine and 7% tetracaine.
14. The formulation of claim 1 , wherein the formulation is formulated for local anesthesia.